Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 ...
Data indicate that GP-2250 has anti-neoplastic effects in virus-negative MCC cells as evidenced by tumor cell viability, proliferation and migration
Source: eagletribune.com